Provided by Tiger Trade Technology Pte. Ltd.

Sequoia Capital Holdings

3,415.03
+38.611.14%
Number of Gainers:64
Number of Losers:32
Number of Flat:4
PE:- -
High:3,429.07
Open:3,376.52
Low:3,376.52
Close:3,376.42
Volume:1.19B
Turnover:255.31B
Market Cap:44.86T
Float Cap:41.93T

Loading ...

STARZ Says Verizon Decides to Remove All STARZ Channels for Fios Customers

MT Newswires Live
·
Oct 01

Oil Price and Bond Yield Pressures Push Indian Stock Market to Six-Month Low

Deep News
·
Oct 01

BOJ Minutes Signal Some Members Favored Faster Rate Hikes to Reach Target Sooner

Deep News
·
Oct 01

Tesla September Registrations Rise Across Europe, Extending Recovery

Reuters
·
Oct 01

Fed's Cook: Inflation Has Been Too High for Too Long, Must Balance Price Stability With Employment

Deep News
·
Oct 01

Foreign Capital Withdrawal Accelerates, Indian Stock Market Faces "Worst Losing Streak in Twenty-Five Years"

Deep News
·
Oct 01

Bank of England Governor Bailey Warns AI Boom Pullback Could Trigger Financial Market Shock

Deep News
·
Oct 01

Kyobo Securities Launches New Equity-Linked Bonds Tied to Samsung and SK hynix

TIPRANKS
·
Oct 01

Thales - Thales and Google Strengthen Their Partnership to Secure Agent-Based AI

THOMSON REUTERS
·
Oct 01

Tesla New Registrations in Sweden +38.4% Year-on-Year in September, Compiler Mobility Sweden Says

THOMSON REUTERS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Goldman Sachs pushes back second Fed rate hike forecast to December, saying need for further tightening is diminishing

Deep News
·
Oct 01

Analyst Maintains Hold on Enbridge, Citing Defensive Assets but Limited Upside Amid Pipeline Competition and Balance Sheet Constraints

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

Starz Entertainment Corp. - Customers Lose Access After Failed Negotiations with Verizon

THOMSON REUTERS
·
Oct 01